Medivation Inc., of San Francisco, said net sales of Xtandi (enzalutamide) capsules, as reported by partner Astellas Pharma Inc., of Tokyo, were $313 million in the third quarter, a 73 percent increase over the same period in 2014. Ex-U.S. net sales of Xtandi, as reported by Astellas, were approximately $205 million for the quarter, or a 71 percent increase over the prior year.